These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 30150466)

  • 1.
    Asante-Appiah E; Liu R; Curry S; McMonagle P; Agrawal S; Carr D; Rokosz L; Lahser F; Bystol K; Chase R; Black S; Ferrari E; Ingravallo P; Tong L; Yu W; Kozlowski J
    Antimicrob Agents Chemother; 2018 Nov; 62(11):. PubMed ID: 30150466
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiviral Activity and Resistance Analysis of NS3/4A Protease Inhibitor Grazoprevir and NS5A Inhibitor Elbasvir in Hepatitis C Virus GT4 Replicons.
    Asante-Appiah E; Curry S; McMonagle P; Ingravallo P; Chase R; Nickle D; Qiu P; Howe A; Lahser FC
    Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28416549
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Combination of Grazoprevir, a Hepatitis C Virus (HCV) NS3/4A Protease Inhibitor, and Elbasvir, an HCV NS5A Inhibitor, Demonstrates a High Genetic Barrier to Resistance in HCV Genotype 1a Replicons.
    Lahser FC; Bystol K; Curry S; McMonagle P; Xia E; Ingravallo P; Chase R; Liu R; Black T; Hazuda D; Howe AY; Asante-Appiah E
    Antimicrob Agents Chemother; 2016 May; 60(5):2954-64. PubMed ID: 26926625
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of an 8-week regimen of grazoprevir plus ruzasvir plus uprifosbuvir compared with grazoprevir plus elbasvir plus uprifosbuvir in participants without cirrhosis infected with hepatitis C virus genotypes 1, 2, or 3 (C-CREST-1 and C-CREST-2, part A): two randomised, phase 2, open-label trials.
    Gane EJ; Pianko S; Roberts SK; Thompson AJ; Zeuzem S; Zuckerman E; Ben-Ari Z; Foster GR; Agarwal K; Laursen AL; Gerstoft J; Gao W; Huang HC; Fitzgerald B; Fernsler D; Li JJ; Grandhi A; Liu H; Su FH; Wan S; Zeng Z; Chen HL; Dutko FJ; Nguyen BT; Wahl J; Robertson MN; Barr E; Yeh WW; Plank RM; Butterton JR; Esteban R
    Lancet Gastroenterol Hepatol; 2017 Nov; 2(11):805-813. PubMed ID: 28802816
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of a two-drug direct-acting antiviral agent regimen ruzasvir 180 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4, 5 or 6.
    Lawitz E; Gane E; Feld JJ; Buti M; Foster GR; Rabinovitz M; Burnevich E; Katchman H; Tomasiewicz K; Lahser F; Jackson B; Shaughnessy M; Klopfer S; Yeh WW; Robertson MN; Hanna GJ; Barr E; Platt HL;
    J Viral Hepat; 2019 Sep; 26(9):1127-1138. PubMed ID: 31108015
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Ng TI; Tripathi R; Reisch T; Lu L; Middleton T; Hopkins TA; Pithawalla R; Irvin M; Dekhtyar T; Krishnan P; Schnell G; Beyer J; McDaniel KF; Ma J; Wang G; Jiang LJ; Or YS; Kempf D; Pilot-Matias T; Collins C
    Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29084747
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of a fixed-dose combination regimen of grazoprevir, ruzasvir, and uprifosbuvir with or without ribavirin in participants with and without cirrhosis with chronic hepatitis C virus genotype 1, 2, or 3 infection (C-CREST-1 and C-CREST-2, part B): two randomised, phase 2, open-label trials.
    Lawitz E; Buti M; Vierling JM; Almasio PL; Bruno S; Ruane PJ; Hassanein TI; Muellhaupt B; Pearlman B; Jancoriene L; Gao W; Huang HC; Shepherd A; Tannenbaum B; Fernsler D; Li JJ; Grandhi A; Liu H; Su FH; Wan S; Dutko FJ; Nguyen BT; Wahl J; Robertson MN; Barr E; Yeh WW; Plank RM; Butterton JR; Yoshida EM
    Lancet Gastroenterol Hepatol; 2017 Nov; 2(11):814-823. PubMed ID: 28802814
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro resistance profile of hepatitis C virus NS5A inhibitor velpatasvir in genotypes 1 to 6.
    Dvory-Sobol H; Han B; Lu J; Yu M; Beran RK; Cheng G; Martin R; Svarovskaia E; Mo H
    J Viral Hepat; 2019 Aug; 26(8):991-1001. PubMed ID: 31009123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cell Culture Studies of the Efficacy and Barrier to Resistance of Sofosbuvir-Velpatasvir and Glecaprevir-Pibrentasvir against Hepatitis C Virus Genotypes 2a, 2b, and 2c.
    Ramirez S; Fernandez-Antunez C; Mikkelsen LS; Pedersen J; Li YP; Bukh J
    Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31818814
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Resistance studies of a dithiazol analogue, DBPR110, as a potential hepatitis C virus NS5A inhibitor in replicon systems.
    Lin HM; Wang JC; Hu HS; Wu PS; Wang WH; Wu SY; Yang CC; Yeh TK; Hsu TA; Jiaang WT; Chao YS; Chern JH; Yueh A
    Antimicrob Agents Chemother; 2013 Feb; 57(2):723-33. PubMed ID: 23165461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The combination of alisporivir plus an NS5A inhibitor provides additive to synergistic anti-hepatitis C virus activity without detectable cross-resistance.
    Chatterji U; Garcia-Rivera JA; Baugh J; Gawlik K; Wong KA; Zhong W; Brass CA; Naoumov NV; Gallay PA
    Antimicrob Agents Chemother; 2014 Jun; 58(6):3327-34. PubMed ID: 24687498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of Ruzasvir (MK-8408): A Potent, Pan-Genotype HCV NS5A Inhibitor with Optimized Activity against Common Resistance-Associated Polymorphisms.
    Tong L; Yu W; Chen L; Selyutin O; Dwyer MP; Nair AG; Mazzola R; Kim JH; Sha D; Yin J; Ruck RT; Davies IW; Hu B; Zhong B; Hao J; Ji T; Zan S; Liu R; Agrawal S; Xia E; Curry S; McMonagle P; Bystol K; Lahser F; Carr D; Rokosz L; Ingravallo P; Chen S; Feng KI; Cartwright M; Asante-Appiah E; Kozlowski JA
    J Med Chem; 2017 Jan; 60(1):290-306. PubMed ID: 27808515
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical characterization of the novel hepatitis C virus NS3 protease inhibitor GS-9451.
    Yang H; Robinson M; Corsa AC; Peng B; Cheng G; Tian Y; Wang Y; Pakdaman R; Shen M; Qi X; Mo H; Tay C; Krawczyk S; Sheng XC; Kim CU; Yang C; Delaney WE
    Antimicrob Agents Chemother; 2014; 58(2):647-53. PubMed ID: 23939899
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Ng TI; Krishnan P; Pilot-Matias T; Kati W; Schnell G; Beyer J; Reisch T; Lu L; Dekhtyar T; Irvin M; Tripathi R; Maring C; Randolph JT; Wagner R; Collins C
    Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28193664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HCV Genotype 6a Escape From and Resistance to Velpatasvir, Pibrentasvir, and Sofosbuvir in Robust Infectious Cell Culture Models.
    Pham LV; Ramirez S; Gottwein JM; Fahnøe U; Li YP; Pedersen J; Bukh J
    Gastroenterology; 2018 Jun; 154(8):2194-2208.e12. PubMed ID: 29454794
    [TBL] [Abstract][Full Text] [Related]  

  • 16. No impact of resistance-associated substitutions on the efficacy of sofosbuvir, velpatasvir, and voxilaprevir for 12 weeks in HCV DAA-experienced patients.
    Sarrazin C; Cooper CL; Manns MP; Reddy KR; Kowdley KV; Roberts SK; Dvory-Sobol H; Svarovskia E; Martin R; Camus G; Doehle BP; Stamm LM; Hyland RH; Brainard DM; Mo H; Gordon SC; Bourliere M; Zeuzem S; Flamm SL
    J Hepatol; 2018 Dec; 69(6):1221-1230. PubMed ID: 30098373
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Resistance analysis in patients with genotype 1-6 HCV infection treated with sofosbuvir/velpatasvir in the phase III studies.
    Hezode C; Reau N; Svarovskaia ES; Doehle BP; Shanmugam R; Dvory-Sobol H; Hedskog C; McNally J; Osinusi A; Brainard DM; Miller MD; Mo H; Roberts SK; O'Leary JG; Shafran SD; Zeuzem S
    J Hepatol; 2018 May; 68(5):895-903. PubMed ID: 29221887
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combinations of lambda interferon with direct-acting antiviral agents are highly efficient in suppressing hepatitis C virus replication.
    Friborg J; Levine S; Chen C; Sheaffer AK; Chaniewski S; Voss S; Lemm JA; McPhee F
    Antimicrob Agents Chemother; 2013 Mar; 57(3):1312-22. PubMed ID: 23274666
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro activity and resistance profile of samatasvir, a novel NS5A replication inhibitor of hepatitis C virus.
    Bilello JP; Lallos LB; McCarville JF; La Colla M; Serra I; Chapron C; Gillum JM; Pierra C; Standring DN; Seifer M
    Antimicrob Agents Chemother; 2014 Aug; 58(8):4431-42. PubMed ID: 24867983
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combinations of two drugs among NS3/4A inhibitors, NS5B inhibitors and non-selective antiviral agents are effective for hepatitis C virus with NS5A-P32 deletion in humanized-liver mice.
    Doi A; Hikita H; Kai Y; Tahata Y; Saito Y; Nakabori T; Yamada R; Kodama T; Sakamori R; Murayama A; Nitta S; Asahina Y; Suemizu H; Tatsumi T; Kato T; Takehara T
    J Gastroenterol; 2019 May; 54(5):449-458. PubMed ID: 30684016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.